Showing 2601-2610 of 3223 results for "".
- Amydis Enrolls First Participants in PROBE, a Phase 1/2a Trial Evaluating a Novel Retinal Tracer in People with Amyotrophic Lateral Sclerosis or Parkinson’s Diseasehttps://modernod.com/news/amydis-announces-enrollment-of-first-participants-in-probe-a-phase-12a-trial-evaluating-a-novel-retinal-tracer-in-people-with-amyotrophic-lateral-sclerosis-or-parkinsons-disease/2481109/Amydis announced dosing of the first patients in the company’s phase 1/2a trial evaluating AMDXP-2011P, a proprietary small molecule retinal imaging agent “retinal tracer” targeting deposits of alpha synuclein (ASYN) and the TAR DNA-binding protein 43 (TDP-43) in patients w
- Frontera Therapeutics Receives Additional IND Clearance for its Lead Program FT-001https://modernod.com/news/frontera-therapeutics-receives-additional-ind-clearance-for-its-lead-program-ft-001/2481106/Frontera Therapeutics announced that its lead program, FT-001, a gene therapy product candidate targeting inherited retinal degenerations (IRDs) with a RPE65 mutation, successfully obtained an IND from the Center for Drug Evaluation (CDE), NMPA, in China. The FDA also cleared an IND for
- Cimerli, First Biosimilar Interchangeable to Lucentis, Set to Launch in the UShttps://modernod.com/news/coherus-to-launch-cimerli-ranibizumab-eqrn-in-the-us/2481103/Coherus BioSciences announced the commercial availability, beginning October 3, 2022, of Cimerli (ranibizumab-eqrn), a biosimilar product interchangeable with Lucentis (ranibizumab injection) for all approved indications. Cimerli was approved by the FDA in August 2022, having met FDA&rs
- Pixium Vision Reaches Enrollment Target in the European Pivotal Trial PRIMAverahttps://modernod.com/news/pixium-vision-reaches-enrollment-target-in-the-european-pivotal-trial-primavera/2481101/Pixium Vision SA announced the completion of patient enrollment in the PRIMAvera pivotal trial in atrophic dry age-related macular degeneration (AMD), also known as geographic atrophy. A total of 38 patients have been enrolled in the PRIMAvera study
- Sight Sciences Announces Completion of Enrollment in SAHARA, a Randomized Clinical Trial of the TearCare System vs Restasishttps://modernod.com/news/sight-sciences-announces-completion-of-enrollment-in-sahara-a-randomized-clinical-trial-of-the-tearcare-system-vs-restasis/2481086/Sight Sciences announced the completion of enrollment in the SAHARA trial, a study designed to evaluate whether an interventional dry eye procedure with the TearCare System is superior in alleviating the signs and symptoms of dry eye disease compared to 6-months of twice daily Restasis&
- New MaximEyes.com Software Designed to Simplify EHR Navigation and Patient Flowhttps://modernod.com/news/new-maximeyescom-software-designed-to-simplify-ehr-navigation-and-patient-flow/2481076/First Insight has introduced MaximEyes.com, which is desinged go allow eye care processionals to access data—anywhere, anytime, from any device—in a web browser or via a local server.
- NIH Researchers Develop Gene Therapy for Rare Ciliopathyhttps://modernod.com/news/nih-researchers-develop-gene-therapy-for-rare-ciliopathy/2481074/Researchers from the National Eye Institute (NEI) have developed a gene therapy that rescues cilia defects in retinal cells affected by a type of Leber congenital amaurosis (LCA), a disease that causes blindness in early childhood. Using patient-derived retina organoids (also known as retinas-in-
- SamaCare’s Prior Authorization Management Platform Available on the ModMed EMRhttps://modernod.com/news/samacares-prior-authorization-management-platform-available-on-the-modmed-emr/2481065/Retina and multi-specialty ophthalmology practices will now be able to synchronize data and share documents between the ModMed all-in-one ophthalmology solution and SamaCare’s prior authorization management platform, according to a SamaCare news release. The interface su
- First US Patient Receives Autologous Stem Cell Therapy to Treat Dry AMDhttps://modernod.com/news/first-us-patient-receives-autologous-stem-cell-therapy-to-treat-dry-amd/2481061/At the National Institutes of Health, a surgical team successfully implanted a patch of tissue made from patient cells with the goal of treating advanced dry age-related macular degeneration (AMD), also known as geographic atrophy. The patient received the therapy as part of
- Lucentis Biosimilar Ranivisio Receives Marketing Authorization from European Commissionhttps://modernod.com/news/european-commission-grants-marketing-authorization-for-ranivisio-for-amd/2481057/Teva Pharmaceuticals announced that it has received marketing authorization from the European Commission for Ranivisio (ranibizumab), a biosimilar of Lucentis. The authorization includes all five indications for which Lucentis is authorized in adults.